Raising venture capital for a SaaS company is hard. Raising it for a quantum computing startup, a clinical-stage biotech, or a hardware device company is a different sport entirely. Different investors, different timelines, different due diligence processes, and different milestones that unlock capital. Generic fundraising advice—build an MVP, get to $1M ARR, raise Series A—simply doesn’t apply.
Specialized startups represent some of the highest-upside opportunities in venture, but they require navigating funding structures designed for businesses where the product might take 5-10 years to reach market, regulatory approval is uncertain, and capital requirements dwarf typical software companies. The founders who succeed raise from investors who genuinely understand their domain, structure rounds around technical milestones rather than revenue, and know how to bridge the gap between early non-dilutive funding and institutional venture capital.
Table of Contents
- Deep Tech and AI Infrastructure Funding
- Biotech and Life Sciences Capital
- Hardware and Physical Products
- Climate Tech and Energy
- Defense and Dual-Use Technology
- Non-Dilutive Funding Sources
- Milestone-Based Financing Structures
- Frequently Asked Questions
Deep Tech and AI Infrastructure Funding
Deep tech covers companies building fundamental technology—quantum computing, advanced materials, photonics, semiconductors, robotics, and AI infrastructure. These companies typically need 5-10 years and $50-200M+ to reach commercial viability.
The funding landscape differs fundamentally from software. Seed rounds are larger ($2-5M instead of $500K-2M), timelines to Series A are longer (2-4 years instead of 12-18 months), and technical milestones replace revenue milestones as proof points.
Who invests in deep tech:
| Fund Name | Focus | Ticket Size | Stage | Notable Portfolio |
|---|---|---|---|---|
| Breakthrough Energy Ventures | Climate, Advanced Energy | $10M-$50M | Series A-C | Commonwealth Fusion, Form Energy |
| Lux Capital | Science-based startups | $5M-$30M | Seed-Series B | Varda Space, Resilience |
| Prelude Ventures | Climate and deep tech | $5M-$25M | Seed-Series B | Multiple cleantech |
| DCVC | Data-driven science | $2M-$20M | Seed-Series B | Recursion, Standard AI |
| Khosla Ventures | Transformative tech | $1M-$50M | Seed-Series C | OpenAI, Impossible Foods |
| Amadeus Capital Partners | Deep tech (Europe) | €2M-€15M | Seed-Series B | Multiple UK/EU deep tech |
| Speedinvest | DeepTech (Europe) | €500K-€5M | Seed-Series A | Various European |
European deep tech has strong funding infrastructure through the European Innovation Council (EIC), Horizon Europe grants, and national agencies like Innovate UK, Bpifrance, and CDTI in Spain.
Milestone-based fundraising for deep tech:
Instead of revenue milestones, deep tech investors fund against technical de-risking: proof of concept (does the physics work?), prototype (can we build it?), pilot (does it work in real-world conditions?), and commercial deployment (can we manufacture and sell at scale?).
Each milestone unlocks the next funding round. A quantum computing company might raise:
- Pre-seed $2M: demonstrate 10-qubit coherence time above X microseconds
- Seed $8M: achieve 50-qubit system with error rates below Y%
- Series A $30M: demonstrate commercial advantage on specific problem class
- Series B $100M: build first commercial system for paying customer
These milestones are set collaboratively with technical advisors and domain investors. They should be aggressive enough to demonstrate progress but achievable within the funded runway.
The deep tech valley of death:
Deep tech startups face a “valley of death” between early academic/government funding (where the science is proven but commercial application is unclear) and VC funding (which requires de-risked technology with clear commercial path). This valley typically occurs between $2-10M raised, after seed funding runs out but before the technology is commercial enough for traditional Series A.
Solutions: national lab partnerships that provide access to expensive equipment without capital expenditure, SBIR/STTR grants in the US (up to $2M non-dilutive), EIC grants in Europe (up to €2.5M), and university spinout funding from tech transfer offices.
Deep tech founders who skip this bridge funding often find themselves raising Series A with insufficient technical validation, unable to command reasonable valuations. The best outcomes come from founders who layer non-dilutive funding, strategic partnerships, and early VC to bridge the valley without excessive dilution.
AI infrastructure specifically:
AI infrastructure companies—companies building compute platforms, training infrastructure, data tools, or AI safety solutions—have emerged as a distinct category since 2022. These companies benefit from: massive corporate R&D budgets flowing into AI (Microsoft, Google, Amazon collectively spending $200B+ annually), clear enterprise customers who understand and value the products, and shorter timelines to commercial validation than deep tech hardware.
The funding dynamics: AI infrastructure seed rounds now average $3-8M (premium over typical software seed), Series A rounds are $15-40M, and valuations are significantly higher than comparable software companies due to perceived strategic value.
Investors pay up because AI infrastructure creates durable competitive advantages—companies that build foundational tools used by thousands of AI developers create network effects and switching costs that software tools rarely achieve.
Biotech and Life Sciences Capital
Biotech fundraising operates by entirely different rules. The product (a drug, medical device, or diagnostic) must be proven safe and effective through multi-year clinical trials before generating revenue. The entire funding structure is built around this reality.
The biotech funding ladder:
| Stage | Capital Required | Timeline | Milestone | Typical Investors |
|---|---|---|---|---|
| Discovery | $1M-$5M | 1-2 years | Target identification | Angels, family offices, university funds |
| Pre-clinical | $5M-$20M | 2-3 years | Animal efficacy, safety data | Seed VC, NIH grants |
| Phase I | $15M-$40M | 1-2 years | Safety in humans, dose finding | Series A VC, biotech funds |
| Phase II | $40M-$100M | 2-4 years | Efficacy signal, patient selection | Series B, crossover funds |
| Phase III | $100M-$500M+ | 3-5 years | Regulatory submission | IPO, big pharma partnership |
Many biotech companies never reach Phase III as standalone entities—they get acquired by pharmaceutical companies after Phase II data shows efficacy signals. This is the most common exit: Merck, Pfizer, Roche, and AstraZeneca collectively spend $50-100B+ annually on biotech acquisitions.
Biotech-specific investors:
Biotech requires investors who understand clinical development, regulatory pathways, and scientific risk. Generic tech VCs don’t belong in biotech—they don’t understand why Phase II efficacy signals matter or why FDA Complete Response Letters are recoverable.
Leading biotech-focused VCs: Atlas Venture (Cambridge, MA—exclusively biotech), ARCH Venture Partners (deep science, first round at university spinouts), Third Rock Ventures (company-creation model, builds biotechs from scratch), OrbiMed (global biotech, $15B under management), Novo Holdings (corporate VC from Novo Nordisk, global), and HealthCap (European biotech specialist, Stockholm).
European biotech ecosystem has strengthened significantly, with UK, Germany, Switzerland, and Netherlands producing successful biotech clusters. London’s MedCity, Munich’s BioCampus, and Basel’s pharma cluster create geographic hubs where academic research, early-stage funding, and large pharma co-exist.
Non-dilutive biotech funding:
Biotech founders can access significant non-dilutive capital before needing VC:
NIH grants (US): SBIR Phase I ($300K), SBIR Phase II ($2M), R01 grants ($500K-2M annually), and program project grants. These fund pre-clinical research without dilution.
ERC and Horizon Europe (EU): European Research Council grants (€1.5-2.5M for starting grants, up to €10M for synergy grants), plus Horizon Europe collaborative grants.
Disease foundations: Michael J. Fox Foundation (Parkinson’s), Cystic Fibrosis Foundation, Gates Foundation, and hundreds of disease-specific organizations fund early research that de-risks programs for VC.
Pharma partnerships: large pharmaceutical companies pay upfront licensing fees for access to early-stage technology—$5-50M upfront plus milestone payments and royalties. This validates technology and funds development without dilution.
Clinical trial design and investor expectations:
Biotech investors focus intensely on clinical trial design. Poor trial design can generate ambiguous data that neither proves nor disproves efficacy, wasting years and millions. Investors will scrutinize:
Patient selection and biomarker strategy: are you treating the right patients? Precision medicine approaches (treating genetically-defined patient subsets) often show cleaner efficacy signals and command premium valuations.
Primary endpoint selection: is your primary endpoint approvable by FDA/EMA? Is it clinically meaningful or just a surrogate marker? Does it differentiate your drug from existing treatments?
Competitive positioning: if you’re developing a drug in a crowded indication (oncology, metabolic disease), you need to demonstrate differentiation from approved drugs and late-stage competitors.
Biotech founders who partner with experienced clinical development consultants before designing Phase II trials dramatically improve success rates. The science might be excellent but the trial design can still fail you.
Hardware and Physical Products
Hardware startups face the most capital-intensive path in venture—they need to finance design, prototyping, tooling, manufacturing setup, and inventory before generating revenue. The economics are brutal: gross margins of 30-50% (versus 70-85% for software), long sales cycles for enterprise hardware, and manufacturing scale-up requiring capital that software companies never need.
The hardware funding reality:
Most VC firms won’t fund hardware at seed stage. The capital requirements are too high, timelines are too long, and margins are too low for typical venture return profiles. Hardware founders must be creative about early funding:
Accelerators with hardware focus: HAX (SOSV’s hardware accelerator, Hong Kong and San Francisco) provides $250K for 5% and access to manufacturing partners in Shenzhen. Bolt (Boston) invests $75K at pre-seed in hardware/software companies. BridgePoint Capital (European hardware focus) backs early-stage hardware companies.
Crowdfunding as validation and capital: Kickstarter and Indiegogo campaigns serve dual purposes—market validation and non-dilutive capital. Ring raised $364K on Indiegogo before going on to sell to Amazon for $1B. Peloton raised $307K on Kickstarter. These campaigns prove demand before you spend millions on tooling.
Government programs: DARPA (US defense research) funds transformative hardware with $1-5M contracts requiring no equity. DoE (Department of Energy) funds clean energy hardware. ARPA-E funds advanced energy technologies. European equivalents include Innovate UK, BMBF in Germany, and Bpifrance.
Contract manufacturing and asset-light models:
Smart hardware founders avoid owning manufacturing—they partner with contract manufacturers (Foxconn, Flextronics, Jabil) to handle production. This reduces capital requirements dramatically but requires minimum order quantities and managing complex supplier relationships.
The design-and-outsource model: design the product in-house, outsource manufacturing, and focus on software/services that improve margins over time. Nest (acquired by Google for $3.2B) sold physical thermostats but generated recurring revenue through subscriptions. Fitbit, despite selling hardware, generated increasing software margins as it scaled.
Investor expectations for hardware:
Hardware investors use different metrics than software investors:
Bill of materials (BOM) cost vs. selling price: gross margins should be 40-60%+ at scale. If your BOM is $80 and you sell for $100, you’re building a business that will never be venture-scalable.
Manufacturing scale milestones: investors want to see a clear path from 1,000 units/month (beta manufacturing) to 100,000+ units/month (commercial scale). This requires contracted manufacturing capacity, quality control processes, and supply chain resilience.
Software monetization layer: hardware companies that attach recurring software revenue trade at much higher multiples. Apple’s services business ($85B+ annual revenue) trades at 30x revenue; iPhone hardware alone would trade at 5x.
Industrial IoT and B2B hardware:
Enterprise hardware and industrial IoT differ from consumer hardware—lower unit volumes, higher ASPs ($10K-500K+ per unit versus $100-500 for consumer), and recurring service/software revenue that justifies venture multiples.
Companies like SparkCognition (industrial AI hardware), Samsara (fleet telematics hardware + software), and Sight Machine (industrial analytics) raised large VC rounds because their hardware enabled high-margin software businesses.
B2B hardware founders should emphasize: recurring revenue from software/services attached to hardware, total cost of ownership advantages over incumbents, ease of integration into existing enterprise systems, and reference customers willing to expand from pilot to full deployment.
Climate Tech and Energy
Climate tech has attracted unprecedented capital since 2020—$100B+ annually globally, with the US Inflation Reduction Act unlocking $369B in clean energy incentives. The funding landscape includes specialized climate VCs, corporate venture arms, government programs, and development finance institutions.
Climate tech funding tiers:
Early-stage climate startups have access to funding unavailable to other sectors:
Philanthropy-backed venture: Breakthrough Energy Ventures (Bill Gates) invests patient capital with 20-year time horizons, removing the typical 10-year VC pressure. Their portfolio includes grid storage, green hydrogen, and advanced nuclear.
Government incentives as revenue: IRA tax credits mean US solar, wind, EVs, and energy storage companies receive substantial government payments that function like revenue. A battery storage company might receive $35/kWh in federal tax credits on top of customer payments, dramatically improving project economics.
Development finance: IFC (World Bank), EBRD, EIB, and national development banks provide patient capital at sub-market rates for climate projects, particularly in emerging markets where commercial capital won’t go.
Offtake agreements: utilities and corporations sign long-term purchase agreements for clean energy before projects are built. These agreements de-risk capital raises by proving revenue before construction.
The climate tech valley of death:
Climate tech faces its own funding gap—between successful lab demonstration and commercial deployment at scale. The gap is larger than deep tech because climate solutions require physical infrastructure (grid connections, permitting, construction) that software doesn’t.
New climate VCs have emerged to bridge this gap: Lowercarbon Capital (Chris Sacca), Congruent Ventures, Clean Energy Ventures, and Prelude Ventures specifically target the gap between early innovation and infrastructure-scale deployment.
Defense and Dual-Use Technology
Defense technology has become one of the fastest-growing VC categories, driven by geopolitical tensions, NATO spending increases, and a generation of defense-focused VCs who believe commercial technology can transform military capability.
The emerging defense VC landscape:
| Fund | Focus | Check Size | Notable Portfolio |
|---|---|---|---|
| Andreessen Horowitz (a16z) | Defense tech broadly | $10M-$100M | Anduril, Shield AI |
| Founders Fund | Hard tech defense | $5M-$50M | Palantir, SpaceX |
| Shield Capital | Defense and intelligence | $5M-$30M | Multiple classified |
| Lux Capital | Dual-use science | $5M-$30M | Varda, Epirus |
| NATO Innovation Fund | Allied nation defense | €5M-€50M | European defense tech |
| Airbus Ventures | Aerospace and defense | $5M-$25M | Various aerospace |
Anduril Industries raised $1.5B+ at a $14B valuation—the defining example of new defense tech. Founded by Palmer Luckey (Oculus founder), Anduril competes directly with Lockheed Martin and Raytheon by offering modern software-first autonomous systems at 1/10th the cost.
Dual-use technology considerations:
Many defense-relevant technologies also have commercial applications: AI vision systems (defense surveillance + commercial logistics), satellite communication (military + commercial broadband), autonomous vehicles (military logistics + commercial trucking), and cybersecurity (government + enterprise).
Dual-use companies have more exit options and larger addressable markets, making them more attractive to commercial VCs who won’t invest in pure defense. The challenge: different procurement cycles, security requirements, and customer relationships for each use case.
ITAR (International Traffic in Arms Regulations) limits what technology you can export and who can invest. Non-US investors face restrictions, limiting your investor pool. Build with ITAR considerations from day one rather than retrofitting compliance later.
Non-Dilutive Funding Sources
Every specialized startup should maximize non-dilutive funding before raising equity. This preserves ownership and often validates the technology with credible third parties.
US non-dilutive programs:
SBIR/STTR (Small Business Innovation Research): the most important US program for deep tech and biotech. Phase I ($50K-$300K) funds feasibility research. Phase II ($750K-$2M) funds full R&D. Phase III is commercialization through private funding or government contracts. Over $4B distributed annually across 11 federal agencies.
NSF Innovation Corps (I-Corps): $50K grants plus intensive customer discovery training. Forces founders to validate commercial applications before spending on R&D. NSF SBIR follows the same agency-specific process.
DOE Loan Programs Office: provides loans and loan guarantees for clean energy technologies. Solyndra (infamously) and Tesla (successfully) both used DOE loans. Not for early-stage but powerful for commercialization.
Advanced Research Projects Agencies (ARPA-E for energy, DARPA for defense, IARPA for intelligence): provide $500K-$10M in research contracts with significant commercial rights retained by founders. DARPA contracts have spawned GPS, the internet, and hundreds of commercial technologies.
European non-dilutive programs:
European Innovation Council (EIC): two main instruments—EIC Pathfinder (€3-4M for breakthrough research), and EIC Accelerator (up to €2.5M grant plus €15M equity investment). The EIC Fund takes equity, so the €15M equity portion is dilutive, but the €2.5M grant portion is not.
Horizon Europe: €95.5B research program. Collaborative grants require consortium of 3+ European entities from different countries. Industrial leadership in areas including digital, climate, and health. Not for pure startups, but university-industry collaborations access this funding.
Innovate UK: UK-specific grants and loans for innovation. Smart Grants (up to £2M), Biomedical Catalyst (for UK life sciences), and sector-specific competitions.
Grants and non-dilutive management:
Managing grant applications is a full-time job. Large research universities, accelerators, and specialized consultants (Grant Writers for Science LLC, KLJ Associates in the US; Katalyze2020 in Europe) help write and manage applications.
The trade-off: grants require extensive reporting, compliance, and overhead. Manage 3-5 active grants simultaneously and you’re spending 20-30% of team capacity on non-commercial activity. Be selective—apply for grants where the funded research aligns with your commercial roadmap, not just because funding is available.
Milestone-Based Financing Structures
Specialized startups increasingly use milestone-based structures that release capital in tranches tied to technical achievements rather than calendar dates or revenue milestones.
Designing milestone frameworks:
Good milestones are: objective (measurable by a third party), achievable (70%+ probability with funded capital), meaningful (demonstrably de-risk the business), and time-bounded (achievable within funded runway of 18-24 months).
For a battery technology startup:
- Milestone 1: Achieve 400 Wh/kg energy density in coin cells (3 months)
- Milestone 2: Demonstrate same performance in pouch cells at 10Ah capacity (9 months)
- Milestone 3: 500-cycle life at C/5 rate with less than 20% capacity fade (18 months)
- Milestone 4: Scale to 100Ah prototype cell from contracted manufacturer (24 months)
Each milestone unlocks the next capital tranche. Miss a milestone and the company renegotiates with investors or shuts down.
Co-investment between grants and equity:
Sophisticated specialized founders layer government grants with equity tranches to minimize dilution. The structure: secure $2M in SBIR/DARPA funding, demonstrate technical milestones with that funding, then raise equity at a de-risked valuation.
Example: company raises $500K equity pre-seed at $4M valuation (12.5% dilution). Secures $1.5M SBIR Phase II. Uses combined $2M to hit technical milestones. Raises $8M Series A at $25M valuation (32% dilution). Total founder dilution: 44.5% for $10M raised—vastly better than raising $10M equity from scratch.
Frequently Asked Questions About Specialized Fundraising
How long does it take to raise for a biotech company compared to software?
Biotech fundraising takes 6-12 months versus 3-5 months for software. The longer timeline reflects investor due diligence requirements (scientific advisory boards, clinical expert networks, regulatory pathway reviews), investment committee processes at larger biotech funds, and the need to align on clinical strategy before committing capital.
Can I raise venture capital for hardware without revenue?
Yes, but it’s harder than software. VCs will fund hardware pre-revenue if you have strong technical validation, experienced team, clear manufacturing path, and defensible technology. The typical pre-revenue hardware seed is $1-3M at $5-10M pre-money valuation. Key proof points: working prototype, identified contract manufacturer, pilot customer commitments (letters of intent, not binding contracts), and clear path to 40%+ gross margins at scale.
Should I pursue SBIR grants or focus entirely on VC fundraising?
Both. SBIR grants don’t preclude VC funding—in fact, they strengthen VC pitches by demonstrating government validation and providing non-dilutive capital. The only constraint: SBIR requires “small business” status (under 500 employees), which isn’t relevant until you’re very large. Apply for SBIR while simultaneously running a VC fundraising process.
What’s the biggest mistake specialized startup founders make in fundraising?
Pitching to generalist VCs who don’t understand the domain. A quantum computing founder pitching to a consumer SaaS investor wastes everyone’s time. Research your target investors thoroughly—do they have PhDs in relevant fields? Have they backed similar companies? Do they understand your technical milestones? Sending a biotech pitch to a software VC generates zero value and burns relationships you might need later.
How do I find deep tech or biotech-specific investors in Europe?
Start with national innovation ecosystems: in the UK, Innovate UK’s network and Deep Science Ventures. In Germany, the Fraunhofer Society spinout network and High-Tech Gründerfonds. In France, Bpifrance’s portfolio of deep tech funds. In the Nordics, Novo Holdings and Lundbeckfond for biotech. Pan-European funds including Speedinvest Deep Tech, Amadeus Capital, and EQT Ventures actively back science-based startups. Databases like Fundreef let you filter by sector specialization and stage to identify exactly which investors have backed deep tech or biotech companies in your geography.
How do defense restrictions affect international fundraising?
ITAR and EAR (Export Administration Regulations) restrict foreign investment in defense-sensitive technologies. CFIUS (Committee on Foreign Investment in the US) reviews and can block acquisitions or investments that threaten national security. Practically: avoid Chinese, Russian, and Middle Eastern investors if your technology has any defense relevance. European and allied nation investors (UK, Germany, France, Japan, Australia) generally pass CFIUS review. Structure your cap table from day one to avoid problematic investors, because cleaning it up later is difficult and expensive.
